Search
for

    Sort by

    Community Join

    990-1000 / 1000+ results

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  133 upvotes 2 years ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community P5P supplementation for fin sides.

      in Treatment  7 upvotes 4 years ago
      P5P supplementation helped reverse finasteride side effects, particularly by lowering prolactin levels and restoring sensitivity. The user experienced significant improvement within a day and full recovery in a few days.

      community Hair loss treatments rated (by gpt-4)

      in Research/Science  250 upvotes 3 years ago
      Rating treatments for hair loss, with the help of GPT-4, according to efficacy, evidence and tolerability; a combination of chemicals from research papers, custom compounds, and some suggestions from other users were included.

      community PG causing irritation when applying RU

      in Research/Science 2 years ago
      The user is experiencing irritation from using PG with RU58841 and is seeking alternative solutions like K&B in the UK. They report redness, itchiness, and flaky skin from the current treatment.

      community What are the alternatives to spironolactone for AGA?

      in Female  9 upvotes 1 year ago
      The user experienced side effects from spironolactone and is seeking alternatives for androgenetic alopecia (AGA), considering saw palmetto but unsure of its effectiveness. They are also exploring the possibility of using topical spironolactone, despite availability challenges.

      community PP405 Update and My Take on Pelage

      in Research/Science  86 upvotes 8 months ago
      Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.